Cybin Inc. (Cybin), a biotechnology company, announced the filing of Form 6-K with the U.S. Securities and Exchange Commission (SEC) for August 2024. The report, signed by CEO Doug Drysdale, includes details of the upcoming Annual and Special Meeting of Shareholders scheduled for August 27, 2024. Shareholders will vote on several key issues, including the appointment of Zeifmans LLP as the auditor, the election of directors, a proposed consolidation of common shares by a ratio of up to 50:1, amendments to the Equity Incentive Plan, the Amended and Restated Rights Plan, and amendments to common share purchase warrants. The meeting will be held virtually, and shareholders can attend and vote online. The management information circular provides comprehensive information on the matters to be voted on, including the background and qualifications of director nominees, and outlines the procedures for proxy voting and appointing proxyholders.

Cybin Inc. (Cybin), a biotechnology company, announced the filing of Form 6-K with the U.S. Securities and Exchange Commission (SEC) for August 2024. The report, signed by CEO Doug Drysdale, includes details of the upcoming Annual and Special Meeting of Shareholders scheduled for August 27, 2024. Shareholders will vote on several key issues, including the appointment of Zeifmans LLP as the auditor, the election of directors, a proposed consolidation of common shares by a ratio of up to 50:1, amendments to the Equity Incentive Plan, the Amended and Restated Rights Plan, and amendments to common share purchase warrants. The meeting will be held virtually, and shareholders can attend and vote online. The management information circular provides comprehensive information on the matters to be voted on, including the background and qualifications of director nominees, and outlines the procedures for proxy voting and appointing proxyholders.